Flotetuzumab
Based on 1 Customer Validation
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.71%
- CAS No.: 1664355-28-5
- Masse moléculaire:58.77 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
V-Lambda-VH_V-Kappa-VH'
Human
CD123 & CD3
Flotetuzumab (0.01 ng/mL, 0.1 ng/mL; 144 h) increases IFN-γ, IL-10, and IL-6 secretion in primary PBMCs[1].
Flotetuzumab (10-6-102 ng/mL; 24 h) shows cytotoxicity against the Kasumi-3 AML cell line using human PBMCs or cynomolgus[1].
Flotetuzumab (0.01 ng/mL, 0.1 ng/mL; 6 d) dose-dependently inhibits leukemic blasts growth[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Primary PBMCs
-
Concentration:0.01 ng/mL, 0.1 ng/mL
-
Incubation Time:6 days
-
Result:Resulted in a dose-dependent depletion of leukemic blasts, accompanied by a concomitant expansion of autologous T cells, up-regulation of the proliferation marker Ki-67, and a proportionally greater expansion of CD8+ cells.
Flotetuzumab (0.5 mg/kg; once every 5 d; for 30 d) improves mouse survival and induces T-cell proliferation in mouse NTPL-146 patient-derived xenograft (PDX) model of acute myeloid leukemia (AML)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:PBMCs-reconstituted tumor model: NSG/β2m-/- mice intradermally implanted with the KG-1a (AML-M0) cells on day 0 and intraperitoneally injected with human PBMCs on day 1[1]
-
Dosage:0.5 μg/kg, 1 μg/kg, and 4 μg/kg;
-
Administration:Peritoneally implantation with mini-osmotic pumps; continuous infusion from days 16 to 22;
-
Result:Inhibited tumor volume significantly.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
V-Lambda-VH_V-Kappa-VH'
ELISA, FACS, Functional assay
-
Immobilized Flotetuzumab can bind Human IL-3R alpha/CD123 Protein (hFc Tag). The EC50 for this effect is 3.75 ng/mL. -
Immobilized Flotetuzumab can bind Human CD3 epsilon/CD3e Protein (ECD, hFc Tag). The EC50 for this effect is 1.33 ng/mL.
Chemical Information
-
CAS No. 1664355-28-5
-
Appearance Liquid
-
Masse moléculaire 58.77 kDa
-
Color Colorless to light yellow
-
SMILES
[Flotetuzumab]
-
Synonyms
MGD006; S80880
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Chichili GR, et al. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates. Sci Transl Med. 2015 May 27;7(289):289ra82. [Content Brief]
[2]. Barwe SP, et al. Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia. J Clin Med. 2022 Feb 28;11(5):1333. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Flotetuzumab Related Classifications
HY-P99623 Related Classifications
Powered by Bioz